congenital adrenal hyperplasia

By Targets:	Apoptosis (4) CFTR (6) CRFR (2) Endogenous Metabolite (4) Glucocorticoid Receptor (4) Isotope-Labeled Compounds (4) Mineralocorticoid Receptor (4) Reference Standards (3)
By Research Areas:	Cancer (5) Cardiovascular Disease (1) Endocrinology (4) Inflammation/Immunology (4) Metabolic Disease (10) Neurological Disease (1)
Click Chemistry:	Alkynes (3)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106203

Crinecerfont SSR-125543	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B1203

Fludrocortisone 9α-Fludrocortisone; 9α-Fluorcortisol	Mineralocorticoid Receptor Glucocorticoid Receptor Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Fludrocortisone (9α-Fludrocortisone) is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency .

HY-106203A

Crinecerfont hydrochloride SSR-125543 hydrochloride	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) hydrochloride is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont hydrochloride blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont hydrochloride improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont hydrochloride can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-113405

21-Deoxycortisol	Endogenous Metabolite	Endocrinology
21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .

HY-113603

Tildacerfont SPR001; LY2371712	CRFR	Metabolic Disease
Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

HY-W741510

21-Deoxy cortisone 21-Desoxycortisone; NSC 38722	Endogenous Metabolite	Cardiovascular Disease
21-Deoxy Cortisone (21-Desoxycortisone; NSC 38722) is a corticosteroid metabolite of 11-ketoprogesterone. It is formed from 11-ketoprogesterone by the cytochrome P450 (CYP) isozyme CYP17A1, but can also be produced by oxidation of 21-deoxycortisone (HY-113405) by 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). Congenital adrenal hyperplasia is an inborn error of metabolism characterized by a deficiency of 21-hydroxylase, and 21-Deoxy Cortisone levels are elevated in patients with congenital adrenal hyperplasia.

HY-113603S

Tildacerfont-d8 SPR001-d₈; LY2371712-d₈	Isotope-Labeled Compounds CRFR	Cancer
Tildacerfont-d₈ (SPR001-d₈; LY2371712-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

HY-156522

CRF1 receptor antagonist-1	CFTR	Endocrinology
CRF1 receptor antagonist-1 (Compound 2) is a CRF1 receptor antagonist. CRF1 receptor antagonist-1 can be used for research of congenital adrenal hyperplasia (CAH) .

HY-113405R

21-Deoxycortisol (Standard)	Reference Standards Endogenous Metabolite	Endocrinology
21-Deoxycortisol (Standard) is the analytical standard of 21-Deoxycortisol. This product is intended for research and analytical applications. 21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .

HY-106203B

(R)-Crinecerfont (R)-SSR-125543	CFTR	Metabolic Disease
(R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106203C

Crinecerfont tosylate SSR-125543 tosylate	CFTR	Metabolic Disease
Crinecerfont (SSR-125543) tosylate is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont tosylate blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont tosylate improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont tosylate can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont tosylate is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-113405S1

21-Deoxycortisol-d8	Isotope-Labeled Compounds Endogenous Metabolite	Endocrinology
21-Deoxycortisol-d₈ is the deuterium labeled 21-Deoxycortisol. 21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .

HY-106203R

Crinecerfont (Standard) SSR-125543 (Standard)	Reference Standards CFTR	Metabolic Disease
Crinecerfont (Standard) is the analytical standard of Crinecerfont (HY-106203). This product is intended for research and analytical applications. Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B1203S

Fludrocortisone-d5 9α-Fludrocortisone-d₅; 9α-Fluorcortisol-d₅	Isotope-Labeled Compounds Mineralocorticoid Receptor Glucocorticoid Receptor Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Fludrocortisone-d₅ (9α-Fludrocortisone-d₅) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

HY-B1203S1

Fludrocortisone-d2 9α-Fludrocortisone-d₂; 9α-Fluorcortisol-d₂	Isotope-Labeled Compounds Mineralocorticoid Receptor Glucocorticoid Receptor Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Fludrocortisone-d₂ (9α-Fludrocortisone-d₂) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

HY-B1203R

Fludrocortisone (Standard) 9α-Fludrocortisone (Standard); 9α-Fluorcortisol (Standard)	Reference Standards Mineralocorticoid Receptor Glucocorticoid Receptor Apoptosis	Metabolic Disease Inflammation/Immunology Cancer
Fludrocortisone (Standard) (9α-Fludrocortisone (Standard)) is the analytical standard of Fludrocortisone (HY-B1203). This product is intended for research and analytical applications. Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113405

21-Deoxycortisol	Classification of Application Fields Endogenous metabolite Disease Research Fields Endocrinology Steroids Source Classification	Endogenous Metabolite
21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .

HY-113405R

21-Deoxycortisol (Standard)	Structural Classification Endogenous metabolite Steroids Source Classification	Reference Standards Endogenous Metabolite
21-Deoxycortisol (Standard) is the analytical standard of 21-Deoxycortisol. This product is intended for research and analytical applications. 21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P72164

	CYP21A2 Protein, Human (His) CYP21; 21 OHase; 21-OHase; CA21H ; CAH1; CP21A_HUMAN; CPS1; CYP21A 2; CYP21A2; CYP21B; Cytochrome P-450c21; Cytochrome P450 21; Cytochrome P450 C21B; Cytochrome P450 XXI; Cytochrome P450; family 21; subfamily A; polypeptide 2; Cytochrome P450; subfamily XXIA steroid 21 hydroxylase;	Human	E. coli
	CYP21A2 Protein, a cytochrome P450 monooxygenase, crucially hydroxylates progesterone and 17alpha-hydroxyprogesterone at C-21, yielding vital intermediates for mineralocorticoid and glucocorticoid biosynthesis in adrenal steroidogenesis. This enzymatic process involves molecular oxygen, with NADPH providing essential electrons via cytochrome P450 reductase (CPR). CYP21A2 plays a pivotal role in regulating adrenal cortex hormone production. CYP21A2 Protein, Human (His) is the recombinant human-derived CYP21A2 protein, expressed by E. coli , with N-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-113603S

Tildacerfont-d8
Tildacerfont-d₈ (SPR001-d₈; LY2371712-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

Tildacerfont-d8

Tildacerfont-d₈ (SPR001-d₈; LY2371712-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont (SPR001; LY2371712) is an orally active, blood-brain barrier-penetrant selective corticotropin-releasing factor type 1 (CRF1) receptor antagonist. Tildacerfont selectively blocks CRF1 receptors, thereby inhibiting the release of pituitary adrenocorticotropic hormone (ACTH). Tildacerfont can be used in research related to congenital adrenal hyperplasia .

HY-113405S1

21-Deoxycortisol-d8
21-Deoxycortisol-d₈ is the deuterium labeled 21-Deoxycortisol. 21-Deoxycortisol is an endogenous metabolite. 21-Deoxycortisol is a sign of congenital adrenal hyperplasia .

HY-B1203S

Fludrocortisone-d5
Fludrocortisone-d₅ (9α-Fludrocortisone-d₅) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

Fludrocortisone-d5

Fludrocortisone-d₅ (9α-Fludrocortisone-d₅) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

HY-B1203S1

Fludrocortisone-d2
Fludrocortisone-d₂ (9α-Fludrocortisone-d₂) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

Fludrocortisone-d2

Fludrocortisone-d₂ (9α-Fludrocortisone-d₂) is the deuterium labeled Fludrocortisone (HY-B1203). Fludrocortisone is an orally active mineralocorticoid and glucocorticoid receptor agonist. Fludrocortisone suppresses pro-inflammatory cytokine expression, reduces CCL2, IL-6, IL-8 levels, upregulates mineralocorticoid receptor (MR) expression, induces PI3K/Akt, GSK-3β, CREB, ERK1/2, mTOR phosphorylation, blocks Tau hyperphosphorylation, prevents apoptosis, promotes survival and proliferation, enhances renal sodium and water transport, increases plasma volume and blood pressure, reduces plasma potassium and renin activity, stimulates erythropoietin expression, modulates uterine receptivity genes, and reverses PP242-induced MUC1 upregulation. Fludrocortisone can be used for the research of congenital adrenal hyperplasia, postural hypotension, and adrenal insufficiency.

Cat. No.	Product Name		Classification

HY-106203

Crinecerfont SSR-125543		Alkynes
Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106203A

Crinecerfont hydrochloride SSR-125543 hydrochloride		Alkynes
Crinecerfont (SSR-125543) hydrochloride is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont hydrochloride blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont hydrochloride improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont hydrochloride can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont hydrochloride is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-106203B

(R)-Crinecerfont (R)-SSR-125543		Alkynes
(R)-Crinecerfont is the R-enantiomer of Crinecerfont (HY-106203). Crinecerfont (SSR-125543) is an orally effective corticotropin-releasing factor receptor type-1 (CRF1 receptor) antagonist. Crinecerfont blocks CRF1 receptor signaling to reduce adrenocorticotropic hormone secretion. Crinecerfont improves hypothalamic-pituitary-adrenal axis negative feedback sensitivity in chronically stressed mice. Crinecerfont can be used for the research of chronic stress conditions and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency . Crinecerfont is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Click Chemistry